Prova Education

New Horizons in Reducing Cardiovascular Risk in T2DM

New Horizons in Reducing Cardiovascular Risk in T2DM
RestartResume
New treatment options are available for our patients with poorly controlled T2DM, but how do we implement them in our practice?

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Suboptimal glycemic control, cardiovascular events, and obesity are just some of the risks associated with type 2 diabetes (T2DM), which often correlate with poor outcomes. This article will review new treatment options available that aim to improve overall outcomes and offer us management strategies for our patients with poorly controlled T2DM.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    John E. Anderson, MD
    Internal Medicine and Diabetes
    The Frist Clinic
    Nashville, TN

    Dr. Anderson has disclosed he receives consulting fees from Abbott Diabetes, Astra Zeneca, Boerhinger Ingelheim, Eli Lilly, Janssen, Mannkind, Merck, Novo Nordisk, and Sanofi; and is a speaker for Astra Zeneca, Eli Lilly, Janssen, Novo Nordisk, and Sanofi.

    Vivian Fonseca, MD, FRCP
    Professor of Medicine and Pharmacology
    Tullis-Tulane Alumni Chair in Diabetes
    Chief, Section of Endocrinology and Metabolism
    Tulane University Health Sciences Center
    New Orleans, Louisiana

    Dr. Fonseca has disclosed he receives consulting fees and is a speaker for Abbott. Asahi, Astra Zeneca, Aventis, Eli Lilly, Intarcia, Novo Nordisk, Sanofi, and Takeda; and has stock options for Algorithms, BRACO4Health, Insulin, and Microbiome Technologies; and has Amgen stock.

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Feidel, PhD has nothing to disclose.
    • Brian McDonough, MD has nothing to disclose.
    • William A. Mencia, MD has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the role of GLP-1RAs and other antihyperglycemic agents in reducing the risk of CV events in T2DM.
    • Compare and contrast the advantages of injectable and novel delivery formats in improving adherence and persistence to antihyperglycemic therapy.
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians, endocrinologists, diabetes educators, nurse practitioners, physician assistants, and nurses who care for patients with T2DM.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Novo Nordisk Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Sign up for the Prova Education newsletters.

Better education for a better you.

* Required
Optional
Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free